Loading...
Please wait, while we are loading the content...
Similar Documents
Epstein-Barr Virus Latent Gene Expression in Primary Effusion Lymphomas Containing Kaposi ’ s Sarcoma – Associated Herpesvirus / Human Herpesvirus -
| Content Provider | Semantic Scholar |
|---|---|
| Author | Horenstein, Marcelo G. Nador, Roland G. Chadburn, Amy Hyjek, Elizabeth M. Inghirami, Giorgio Knowles, Daniel M. Cesarman, Ethel |
| Copyright Year | 1997 |
| Abstract | Primary effusion (body cavity–based) lymphoma (PEL) is a variable subset of lymphoma cells. Qp-initiated mRNA, enrecently recognized subtype of malignant lymphoma that coding only EBNA1 and characteristic of latencies I and II, exhibits distinctive clinical and biological features, most nowas positive in all PEL cases. Wpand Cp-initiated mRNAs, tably its usual infection with the Kaposi’s sarcoma–associencoding all EBNAs and characteristic of latency III, were ated herpesvirus (KSHV). The vast majority of cases also negative in all cases. LMP1 mRNA, expressed in latencies II contain Epstein-Barr virus (EBV). This dual viral infection is and III, was present in three cases of PEL, although at very the first example of a consistent dual herpesviral infection low levels that were not detectable at the protein level by in a human neoplasm and provides a unique model to study immunohistochemistry. Low levels of LMP2A mRNA were viral interactions. We analyzed the pattern of EBV latent detected in all cases. BZLF1, an early-intermediate lytic gene expression to determine the pathogenic role of this phase marker, was weakly positive in four cases, suggesting agent in PELs. We examined five PELs coinfected with EBV a productive viral infection in a very small proportion of cells, and KSHV by reverse transcription-polymerase chain reacwhich was confirmed by ZEBRA antigen expression. Theretion (RT-PCR), in situ hybridization, and immunohistochemfore, PELs exhibit a restricted latency pattern, with expresistry. EBER1 mRNA, a consistent marker of viral latency, was sion of EBNA1 in all cases, and low LMP1 and LMP2A levels. positive in all PEL cases, although at lower levels than in q 1997 by The American Society of Hematology. the non-PEL controls due to EBER1 expression by only a |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.bloodjournal.org/content/bloodjournal/90/3/1186.full.pdf?sso-checked=true |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
